Loading...
Lazertinib: First Approval
Lazertinib (LECLAZA(®)) is an oral, third-generation, epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) being developed by Yuhan and Janssen Biotech for the treatment of non-small cell lung cancer (NSCLC). It is a brain-penetrant, irreversible EGFR-TKI that targets the T790M mu...
Na minha lista:
| Udgivet i: | Drugs |
|---|---|
| Hovedforfatter: | |
| Format: | Artigo |
| Sprog: | Inglês |
| Udgivet: |
Springer International Publishing
2021
|
| Fag: | |
| Online adgang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC8217052/ https://ncbi.nlm.nih.gov/pubmed/34028784 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s40265-021-01533-x |
| Tags: |
Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!
|